Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. INBS
INBS logo

INBS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.281
Open
3.920
VWAP
4.08
Vol
72.45K
Mkt Cap
6.58M
Low
3.870
Amount
295.86K
EV/EBITDA(TTM)
--
Total Shares
1.60M
EV
5.57M
EV/OCF(TTM)
--
P/S(TTM)
0.87
Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
Show More

Events Timeline

(ET)
2026-02-25
08:50:00
Intelligent Bio Solutions Ships First Fingerprinting Drug Screening Readers
select
2026-02-24 (ET)
2026-02-24
08:50:00
Intelligent Bio Solutions Partners with Bouygues UK
select
2026-02-12 (ET)
2026-02-12
08:40:00
INBS Reports Q2 Revenue of $896,774, Up 47% Year-Over-Year
select
2026-02-05 (ET)
2026-02-05
08:40:00
Intelligent Bio Solutions Expects Over 100% Sales Growth in Q2
select
2026-01-28 (ET)
2026-01-28
08:40:00
Intelligent Bio Solutions Launches Clinical Study to Support FDA Submission
select
2026-01-09 (ET)
2026-01-09
17:10:00
Intelligent Bio Solutions Files to Sell 6.9M Shares of Common Stock
select
2026-01-05 (ET)
2026-01-05
09:40:00
Intelligent Bio Solutions Inc Trading Resumes
select
2026-01-05
09:40:00
Intelligent Bio Solutions Inc Trading Halted Due to Volatility
select
2025-12-31 (ET)
2025-12-31
17:30:00
Intelligent Bio Solutions Issues 2.3M Shares to Raise $10M
select
2025-12-31
17:30:00
S&P 500 Ends Year Up About 17%, Sable Offshore Rises 10.9%
select

News

stocktwits
8.5
02-25stocktwits
Intelligent Bio Solutions Shares Rise 11% on Manufacturing Partnership Announcement
  • Stock Surge: Intelligent Bio Solutions Inc. (INBS) shares rose 11% in pre-market trading following the announcement of a new manufacturing partnership with Syrma Johari MedTech, reflecting strong market confidence in its new product rollout.
  • Capacity Expansion: The company reported that its manufacturing capacity has increased to four times its previous level, which is expected to reduce annual production costs by over 40%, thereby enhancing gross margins by approximately 20 percentage points each year, significantly boosting profitability.
  • Market Deployment: The newly launched Intelligent Fingerprinting Drug Screening Readers are being deployed across various sectors including construction, transportation, logistics, and manufacturing in the U.K. and Europe, indicating an increasing market penetration in these critical areas.
  • Future Outlook: Intelligent Bio Solutions has also doubled its in-house production capacity for test strips and anticipates additional shipments in 2026 as it prepares for entry into the U.S. market, further expanding its market share.
seekingalpha
9.5
02-12seekingalpha
Intelligent Bio Solutions Reports Q2 Earnings
  • Earnings Report: Intelligent Bio Solutions reported a Q2 GAAP EPS of -$2.82, indicating ongoing losses despite a significant revenue increase of 45.9% year-over-year to $0.89 million, highlighting challenges in achieving profitability.
  • Revenue Growth: The company's revenue rose from $0.61 million in the same quarter last year to $0.89 million, reflecting a 45.9% increase, which suggests improved market demand for its products or services, yet ongoing cost management remains crucial for future profitability.
  • Funding Initiative: Intelligent Bio Solutions is launching a $10 million private placement aimed at financing future R&D and market expansion, which could enhance the company's financial flexibility and support long-term growth objectives.
  • Market Rating: According to Seeking Alpha's Quant Rating, Intelligent Bio Solutions' market performance is under scrutiny; while revenue growth is notable, persistent losses may undermine investor confidence, necessitating close monitoring of future financial results.
Newsfilter
9.5
02-12Newsfilter
Intelligent Bio Solutions Reports Strong Fiscal 2026 Q2 Results
  • Significant Revenue Growth: For the first half of fiscal 2026, Intelligent Bio Solutions reported total revenue exceeding $2 million, reflecting a 36% year-over-year increase, indicating strong demand and sustainable growth potential in the non-invasive drug testing market.
  • Doubling of Reader Sales: In Q2, reader sales reached $246,519, up 104% year-over-year, significantly expanding the company's customer base and establishing a solid foundation for future recurring revenue.
  • Improved Gross Margins: The gross profit margin for the first half of fiscal 2026 increased to 49%, a 10% improvement from the same period last year, showcasing enhanced operational efficiency and strengthening the company's competitive position.
  • Strategic Investments and Partnerships: The company closed a $10 million private placement and formed a strategic alliance with Vlepis Pty Ltd, aiming to enter the rapidly growing consumer health monitoring market and broaden revenue opportunities.
Newsfilter
9.5
02-05Newsfilter
Intelligent Bio Solutions Expects Record Revenue Growth in Q2
  • Revenue Growth Expectation: Intelligent Bio Solutions anticipates approximately $2.01 million in revenue for fiscal Q2 2026, reflecting a 36% year-over-year increase, indicating strong growth potential across all product categories.
  • Surge in Reader Sales: Reader sales are expected to more than double year-over-year in Q2, which not only expands the installed base but also drives sustained recurring revenue, further solidifying the company's razor-razorblade business model.
  • Comprehensive Product Growth: For the first half of fiscal 2026, cartridge sales are projected to increase by 38%, while other sales (accessories, training) are expected to rise by 10%, demonstrating the company's competitive strength and ongoing customer demand.
  • Enhanced Market Confidence: The CEO emphasized that the ongoing customer adoption and demand for consumables lay a solid foundation for future revenue growth, which is expected to further enhance market share and bolster confidence in the commercial strategy.
Newsfilter
9.0
01-28Newsfilter
Intelligent Bio Solutions Launches Clinical Study for FDA Clearance
  • Clinical Study Launch: Intelligent Bio Solutions has commenced its clinical study program to support the FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, with full data analysis expected by the end of March 2026, marking a pivotal step for the company's entry into the U.S. market.
  • Partnership with Cliantha: The company has partnered with Cliantha Research, leveraging their extensive regulatory and clinical trial expertise to ensure the study's effectiveness and compliance, thereby enhancing its competitive position in the market.
  • Significant Market Potential: The U.S. drug screening market generates billions annually, and the company's non-invasive fingerprint technology offers superior hygiene and convenience compared to traditional urine and blood testing methods, which is expected to attract a broader customer base.
  • Distinct Technological Advantages: With over 500,000 tests sold outside the U.S., the Intelligent Fingerprinting Drug Screening System demonstrates unique advantages across multiple high-value segments, such as workplace testing and law enforcement applications, further driving the company's global market expansion.
stocktwits
8.5
01-12stocktwits
Intelligent Bio Solutions (INBS) Partners with Syrma Johari MedTech, Stock Soars 132%
  • Manufacturing Partnership: INBS's collaboration with Syrma Johari MedTech is expected to reduce annual production costs by 40% and increase gross margins by 20 percentage points while quadrupling manufacturing capacity, positioning the company for a U.S. market launch in 2026.
  • Successful Private Placement: The company announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock, raising approximately $10 million, thereby strengthening its financial position for future business expansion.
  • Strong Stock Surge: INBS stock closed up 132% on December 31, 2025, and surged 337% from the close on December 30, 2025, to January 9, 2026, becoming a favorite among retail traders, indicating robust market interest.
  • Nasdaq Compliance Restored: On January 7, 2026, INBS was notified by Nasdaq that it regained compliance to trade, maintaining a closing bid price of $1.00 or higher for 14 consecutive trading days, which bolstered investor confidence.

Valuation Metrics

The current forward P/E ratio for Intelligent Bio Solutions Inc (INBS.O) is 2.25, compared to its 5-year average forward P/E of -1.42. For a more detailed relative valuation and DCF analysis to assess Intelligent Bio Solutions Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.42
Current PE
2.25
Overvalued PE
0.88
Undervalued PE
-3.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
15.50
Current PS
0.28
Overvalued PS
50.30
Undervalued PS
-19.31

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks that fell over 20% yesterday
Intellectia · 19 candidates
Price Change Pct: $-100.00 - $-20.00
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
890.11K
IOBT logo
IOBT
IO Biotech Inc
14.94M
VERO logo
VERO
Venus Concept Inc
3.51M
IBG logo
IBG
Innovation Beverage Group Ltd
3.33M
JFBR logo
JFBR
Jeffs Brands Ltd
2.33M
SURG logo
SURG
Surgepays Inc
25.72M

Whales Holding INBS

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Intelligent Bio Solutions Inc (INBS) stock price today?

The current price of INBS is 4.1 USD — it has increased 1.11

What is Intelligent Bio Solutions Inc (INBS)'s business?

Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.

What is the price predicton of INBS Stock?

Wall Street analysts forecast INBS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Intelligent Bio Solutions Inc (INBS)'s revenue for the last quarter?

Intelligent Bio Solutions Inc revenue for the last quarter amounts to 896.77K USD, increased 47.62

What is Intelligent Bio Solutions Inc (INBS)'s earnings per share (EPS) for the last quarter?

Intelligent Bio Solutions Inc. EPS for the last quarter amounts to -2.82 USD, decreased -43.15

How many employees does Intelligent Bio Solutions Inc (INBS). have?

Intelligent Bio Solutions Inc (INBS) has 16 emplpoyees as of March 09 2026.

What is Intelligent Bio Solutions Inc (INBS) market cap?

Today INBS has the market capitalization of 6.58M USD.